New York, New York-- (Newsfile Corp. - February 17, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Applied Therapeutics, Inc. (NASDAQ: ...

New York, New York-- (Newsfile Corp. - February 15, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Applied Therapeutics, Inc. (NASDAQ: ...

The Company’s lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor for the treatment of CNS rare metabolic diseases, including Galactosemia.

The Company’s lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor for the treatment of CNS rare metabolic diseases, including Galactosemia.

Look closely at this image, stripped of its caption, and join the moderated conversation about what you and other students see. By The Learning Network Look closely at this image, stripped of ...

We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.

After hours: February 14 at 7:52:09 PM EST ...